FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114838862> ?p ?o ?g. }

• W2114838862 endingPage "55" @default.
• W2114838862 startingPage "46" @default.
• W2114838862 abstract "PurposeThe study was conducted to evaluate the clinical results of resection for retroperitoneal soft tissue sarcoma (STS) with vascular involvement.MethodsThe study group consisted of consecutive patients (mean age, 52 years) who underwent surgery for retroperitoneal STS with vascular involvement. The procedures were performed between 1988 and 2004. Vessel involvement by STS was classified as type I, artery and vein; type II, only artery; type III, only vein; and type IV, neither artery nor vein (excluded from the analysis). Patient data were prospectively gathered in a computerized database and retrospectively analyzed.ResultsOf 141 patients with retroperitoneal STS, 25 (17.7%) underwent surgery for tumors with vascular involvement. The most common vascular involvement pattern was vein only (type III) at 64%. Arterial and vein (type I) and arterial only (type II) involvement were observed in 16% and 20% of the cases, respectively. STS originating from the vessel wall (primary vessel involvement) was seen in eight patients, and 17 patients had secondary vascular involvement. Resection and vascular repair were done in 22 patients (no vascular repair in three patients due to ligation of the external iliac vein in one patient, and debulking procedures in two). All patients with arterial involvement (type I and II) had arterial reconstruction consisting of aortic replacement (Dacron, n = 3; and expanded polytetrafluoroethylene [ePTFE], n = 2), iliac repair (Dacron, n = 3), and truncal reimplantation (n = 1). The inferior vena cava (6 ePTFE tube grafts, 3 ePTFE patches, 2 venoplasties), iliac vein (1 ePTFE bypass, 1 Dacron bypass, 1 venous patch), and superior mesenteric vein (1 anastomosis, 1 Dacron bypass) were restored in 80% of the patients (n = 16) with either arterial and venous or only venous involvement (type I and type III setting). Morbidity was 36% (hemorrhage, others), and mortality was 4%. At a median follow-up of 19.3 months (interquartile range, 12.8 to 49.9 months) the arterial patency rate was 88.9%, and the venous patency rate was 93.8% (primary and secondary). Thrombosis developed in one arterial and venous (type I) iliac reconstruction due to a perforated sigmoid diverticulitis 12 months after surgery. The local control rate was 82.4%. The 2-year and 5-year survival rates were 90% and 66.7% after complete resection with tumor-free resection margins (n = 10 patients, median survival not reached at latest follow-up). The median survival was 21 months in patients with complete resection but positive resection margins (n = 7) and 8 months in patients with incomplete tumor clearance (n = 8, persistent local disease or metastasis).ConclusionsPatency rates and an acceptable surgical risk underline the value of en bloc resection of retroperitoneal STS together with involvement of blood vessels. The oncologic outcome is positive, especially after complete resection with tumor-free resection margins. A classification of vascular involvement can be used to plan resection and vascular replacement as well as to compare results among reports in a standardized fashion. The study was conducted to evaluate the clinical results of resection for retroperitoneal soft tissue sarcoma (STS) with vascular involvement. The study group consisted of consecutive patients (mean age, 52 years) who underwent surgery for retroperitoneal STS with vascular involvement. The procedures were performed between 1988 and 2004. Vessel involvement by STS was classified as type I, artery and vein; type II, only artery; type III, only vein; and type IV, neither artery nor vein (excluded from the analysis). Patient data were prospectively gathered in a computerized database and retrospectively analyzed. Of 141 patients with retroperitoneal STS, 25 (17.7%) underwent surgery for tumors with vascular involvement. The most common vascular involvement pattern was vein only (type III) at 64%. Arterial and vein (type I) and arterial only (type II) involvement were observed in 16% and 20% of the cases, respectively. STS originating from the vessel wall (primary vessel involvement) was seen in eight patients, and 17 patients had secondary vascular involvement. Resection and vascular repair were done in 22 patients (no vascular repair in three patients due to ligation of the external iliac vein in one patient, and debulking procedures in two). All patients with arterial involvement (type I and II) had arterial reconstruction consisting of aortic replacement (Dacron, n = 3; and expanded polytetrafluoroethylene [ePTFE], n = 2), iliac repair (Dacron, n = 3), and truncal reimplantation (n = 1). The inferior vena cava (6 ePTFE tube grafts, 3 ePTFE patches, 2 venoplasties), iliac vein (1 ePTFE bypass, 1 Dacron bypass, 1 venous patch), and superior mesenteric vein (1 anastomosis, 1 Dacron bypass) were restored in 80% of the patients (n = 16) with either arterial and venous or only venous involvement (type I and type III setting). Morbidity was 36% (hemorrhage, others), and mortality was 4%. At a median follow-up of 19.3 months (interquartile range, 12.8 to 49.9 months) the arterial patency rate was 88.9%, and the venous patency rate was 93.8% (primary and secondary). Thrombosis developed in one arterial and venous (type I) iliac reconstruction due to a perforated sigmoid diverticulitis 12 months after surgery. The local control rate was 82.4%. The 2-year and 5-year survival rates were 90% and 66.7% after complete resection with tumor-free resection margins (n = 10 patients, median survival not reached at latest follow-up). The median survival was 21 months in patients with complete resection but positive resection margins (n = 7) and 8 months in patients with incomplete tumor clearance (n = 8, persistent local disease or metastasis). Patency rates and an acceptable surgical risk underline the value of en bloc resection of retroperitoneal STS together with involvement of blood vessels. The oncologic outcome is positive, especially after complete resection with tumor-free resection margins. A classification of vascular involvement can be used to plan resection and vascular replacement as well as to compare results among reports in a standardized fashion." @default.
• W2114838862 created "2016-06-24" @default.
• W2114838862 creator A5008575230 @default.
• W2114838862 creator A5016509084 @default.
• W2114838862 creator A5016954466 @default.
• W2114838862 creator A5030930203 @default.
• W2114838862 creator A5033871807 @default.
• W2114838862 creator A5036032282 @default.
• W2114838862 creator A5045340946 @default.
• W2114838862 creator A5067780549 @default.
• W2114838862 creator A5075338963 @default.
• W2114838862 date "2006-07-01" @default.
• W2114838862 modified "2023-10-12" @default.
• W2114838862 title "Clinical results of surgery for retroperitoneal sarcoma with major blood vessel involvement" @default.
• W2114838862 cites W1589353055 @default.
• W2114838862 cites W1987958251 @default.
• W2114838862 cites W1996916689 @default.
• W2114838862 cites W2001459781 @default.
• W2114838862 cites W2003320703 @default.
• W2114838862 cites W2007063435 @default.
• W2114838862 cites W2009072766 @default.
• W2114838862 cites W2009350546 @default.
• W2114838862 cites W2016036520 @default.
• W2114838862 cites W2026849826 @default.
• W2114838862 cites W2027688812 @default.
• W2114838862 cites W2030391415 @default.
• W2114838862 cites W2036395588 @default.
• W2114838862 cites W2041154502 @default.
• W2114838862 cites W2043040300 @default.
• W2114838862 cites W2045080044 @default.
• W2114838862 cites W2053201545 @default.
• W2114838862 cites W2053714893 @default.
• W2114838862 cites W205567039 @default.
• W2114838862 cites W2081256130 @default.
• W2114838862 cites W2085297667 @default.
• W2114838862 cites W2086608998 @default.
• W2114838862 cites W2103961762 @default.
• W2114838862 cites W2108745249 @default.
• W2114838862 cites W2112022998 @default.
• W2114838862 cites W2275599683 @default.
• W2114838862 cites W2409992611 @default.
• W2114838862 cites W4293241248 @default.
• W2114838862 doi "https://doi.org/10.1016/j.jvs.2006.03.001" @default.
• W2114838862 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16828425" @default.
• W2114838862 hasPublicationYear "2006" @default.
• W2114838862 type Work @default.
• W2114838862 sameAs 2114838862 @default.
• W2114838862 citedByCount "147" @default.
• W2114838862 countsByYear W21148388622012 @default.
• W2114838862 countsByYear W21148388622013 @default.
• W2114838862 countsByYear W21148388622014 @default.
• W2114838862 countsByYear W21148388622015 @default.
• W2114838862 countsByYear W21148388622016 @default.
• W2114838862 countsByYear W21148388622017 @default.
• W2114838862 countsByYear W21148388622018 @default.
• W2114838862 countsByYear W21148388622019 @default.
• W2114838862 countsByYear W21148388622020 @default.
• W2114838862 countsByYear W21148388622021 @default.
• W2114838862 countsByYear W21148388622022 @default.
• W2114838862 countsByYear W21148388622023 @default.
• W2114838862 crossrefType "journal-article" @default.
• W2114838862 hasAuthorship W2114838862A5008575230 @default.
• W2114838862 hasAuthorship W2114838862A5016509084 @default.
• W2114838862 hasAuthorship W2114838862A5016954466 @default.
• W2114838862 hasAuthorship W2114838862A5030930203 @default.
• W2114838862 hasAuthorship W2114838862A5033871807 @default.
• W2114838862 hasAuthorship W2114838862A5036032282 @default.
• W2114838862 hasAuthorship W2114838862A5045340946 @default.
• W2114838862 hasAuthorship W2114838862A5067780549 @default.
• W2114838862 hasAuthorship W2114838862A5075338963 @default.
• W2114838862 hasBestOaLocation W21148388621 @default.
• W2114838862 hasConcept C121608353 @default.
• W2114838862 hasConcept C126322002 @default.
• W2114838862 hasConcept C126838900 @default.
• W2114838862 hasConcept C136948725 @default.
• W2114838862 hasConcept C141071460 @default.
• W2114838862 hasConcept C142724271 @default.
• W2114838862 hasConcept C2776820930 @default.
• W2114838862 hasConcept C2777202286 @default.
• W2114838862 hasConcept C2777575454 @default.
• W2114838862 hasConcept C2778256501 @default.
• W2114838862 hasConcept C2778629024 @default.
• W2114838862 hasConcept C2778692183 @default.
• W2114838862 hasConcept C2779033008 @default.
• W2114838862 hasConcept C2780427987 @default.
• W2114838862 hasConcept C2781100745 @default.
• W2114838862 hasConcept C71924100 @default.
• W2114838862 hasConceptScore W2114838862C121608353 @default.
• W2114838862 hasConceptScore W2114838862C126322002 @default.
• W2114838862 hasConceptScore W2114838862C126838900 @default.
• W2114838862 hasConceptScore W2114838862C136948725 @default.
• W2114838862 hasConceptScore W2114838862C141071460 @default.
• W2114838862 hasConceptScore W2114838862C142724271 @default.
• W2114838862 hasConceptScore W2114838862C2776820930 @default.
• W2114838862 hasConceptScore W2114838862C2777202286 @default.
• W2114838862 hasConceptScore W2114838862C2777575454 @default.
• W2114838862 hasConceptScore W2114838862C2778256501 @default.
• W2114838862 hasConceptScore W2114838862C2778629024 @default.

• next